Expertise in
20
conditions

Dr. Ashkan Emadi

Hematology
West Virginia University Hospitals
1 Medical Center Dr, 
Morgantown, WV 
26 Years of Experience
Expertise in
20
conditions
West Virginia University Hospitals
1 Medical Center Dr, 
Morgantown, WV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ashkan Emadi is a Hematologist in Morgantown, West Virginia. Dr. Emadi has been practicing medicine for over 26 years is highly rated in 20 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 108 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
University Of Maryland Medical Center
West Virginia University Hospitals, Inc
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

West Virginia University Hospitals
1 Medical Center Dr, Morgantown, WV 26506

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: February 05, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Pegcrisantaspase
Study Phase: Phase 1
2157GCCC: a Phase I Trial of Calaspargase Pegol-mknl in Combination with High Dose Cytarabine and Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
2157GCCC: a Phase I Trial of Calaspargase Pegol-mknl in Combination with High Dose Cytarabine and Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drug: Calaspargase pegol-mknl
Study Phase: Phase 1
A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Procedure, Drug
Study Phase: Phase 1
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma
A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma
Enrollment Status: Terminated
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations
1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations
Enrollment Status: Completed
Publish Date: March 12, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

108 Total Publications

Artificial Intelligence and Machine Learning in Sexual Health and Dysfunction Across the Cancer Care Continuum: A Systematic Review.
Artificial Intelligence and Machine Learning in Sexual Health and Dysfunction Across the Cancer Care Continuum: A Systematic Review.
Journal: Cancers
Published: August 25, 2025
Similar Doctors
Expertise in
36
conditions
Dr. Michael Craig
Hematology
Expertise in
36
conditions
Dr. Michael Craig
Hematology

Mon Health Cancer Center

1200 J D Anderson Dr, 
Morgantown, WV 
 (0.9 miles away)
304-598-6560
Languages Spoken:
English
See accepted insurances

Michael Craig is a Hematologist in Morgantown, West Virginia. Dr. Craig is highly rated in 36 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
17
conditions
Dr. Mohammed Almubarak
Hematology
Expertise in
17
conditions
Dr. Mohammed Almubarak
Hematology

West Virginia University Hospitals

1 Medical Center Dr, 
Morgantown, WV 
 (0.1 miles away)
304-293-4229
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mohammed Almubarak is a Hematologist in Morgantown, West Virginia. Dr. Almubarak is highly rated in 17 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Bone Marrow Aspiration.

Expertise in
18
conditions
Dr. Radhakrishnan Ramchandren
Hematology
Expertise in
18
conditions
Dr. Radhakrishnan Ramchandren
Hematology

Office

5115 Centre Ave Fl 2, 
Pittsburgh, PA 
 (55.2 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Radhakrishnan Ramchandren is a Hematologist in Pittsburgh, Pennsylvania. Dr. Ramchandren is highly rated in 18 conditions, according to our data. His top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Emadi's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile